Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Cattaneo, C.; Salmanton-Garcia, J.; Marchesi, F.; El-Ashwah, S.; Itri, F.; Weinbergerova, B.; Gomes Da Silva, M.; Dargenio, M.; Davila-Valls, J.; Martin-Perez, S.; Farina, F.; Van Doesum, J.; Valkovic, T.; Besson, C.; Poulsen, C. B.; Lopez-Garcia, A.; Zak, P.; Schonlein, M.; Piukovics, K.; Jaksic, O.; Cabirta, A.; Ali, N.; Sili, U.; Fracchiolla, N.; Dragonetti, Giulia; Adzic-Vukicevic, T.; Marchetti, M.; Machado, M.; Glenthoj, A.; Finizio, O.; Demirkan, F.; Blennow, O.; Tisi, M. C.; Omrani, A. S.; Navratil, M.; Racil, Z.; Novak, J.; Magliano, G.; Jimenez, M.; Garcia-Vidal, C.; Erben, N.; Del Principe, M. I.; Buquicchio, C.; Bergantim, R.; Batinic, J.; Al-Khabori, M.; Verga, L.; Szotkowski, T.; Samarkos, M.; Ormazabal-Velez, I.; Meers, S.; Maertens, J.; Pinczes, L. I.; Hoenigl, M.; Drgona, L.; Cuccaro, A.; Bilgin, Y. M.; Aujayeb, A.; Rahimli, L.; Grafe, S.; Sciume, M.; Mladenovic, M.; Colak, G. M.; Sacchi, M. V.; Nordlander, A.; Berg Venemyr, C.; Hanakova, M.; Garcia-Pouton, N.; Emarah, Z.; Zambrotta, G. P. M.; Nunes Rodrigues, R.; Cordoba, R.; Mendez, G. -A.; Biernat, M. M.; Cornely, O. A.; Pagano, Livio

doi:10.3390/cancers14225530

Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

Cattaneo, C., Salmanton-Garcia, J., Marchesi, F., El-Ashwah, S., Itri, F., Weinbergerova, B., Gomes Da Silva, M., Dargenio, M., Davila-Valls, J., Martin-Perez, S., Farina, F., Van Doesum, J., Valkovic, T., Besson, C., Poulsen, C. B., Lopez-Garcia, A., Zak, P., Schonlein, M., Piukovics, K., Jaksic, O., Cabirta, A., Ali, N., Sili, U., Fracchiolla, N., Dragonetti, G., Adzic-Vukicevic, T., Marchetti, M., Machado, M., Glenthoj, A., Finizio, O., Demirkan, F., Blennow, O., Tisi, M. C., Omrani, A. S., Navratil, M., Racil, Z., Novak, J., Magliano, G., Jimenez, M., Garcia-Vidal, C., Erben, N., Del Principe, M. I., Buquicchio, C., Bergantim, R., Batinic, J., Al-Khabori, M., Verga, L., Szotkowski, T., Samarkos, M., Ormazabal-Velez, I., Meers, S., Maertens, J., Pinczes, L. I., Hoenigl, M., Drgona, L., Cuccaro, A., Bilgin, Y. M., Aujayeb, A., Rahimli, L., Grafe, S., Sciume, M., Mladenovic, M., Colak, G. M., Sacchi, M. V., Nordlander, A., Berg Venemyr, C., Hanakova, M., Garcia-Pouton, N., Emarah, Z., Zambrotta, G. P. M., Nunes Rodrigues, R., Cordoba, R., Mendez, G. -., Biernat, M. M., Cornely, O. A., Pagano, L., Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey, <<CANCERS>>, 2022; 14 (22): 5530-5538. [doi:10.3390/cancers14225530] [https://hdl.handle.net/10807/223847]